Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05577182
Other study ID # INCA 32459-101
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date November 14, 2022
Est. completion date April 10, 2026

Study information

Verified date June 2024
Source Incyte Corporation
Contact Incyte Corporation Call Center (US)
Phone 1.855.463.3463
Email medinfo@incyte.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, open-label, single-arm study to investigate the safety, tolerability, PK, pharmacodynamics and preliminary activity of INCA32459 in participants with selected advanced malignancies. Part 1 (dose escalation) will determine the recommended dose of INCA 32459 for expansion (RDE) and the maximum tolerated dose (MTD). Part 2 (dose expansion) will further evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of INCA 32459 at the recommended dose(s) for expansion in 2 tumor-specific cohorts.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date April 10, 2026
Est. primary completion date April 10, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically or cytologically confirmed advanced malignancies as follows: 1. Part 1 only: Participants with the select advanced malignancies as specified in the protocol. 2. Part 2 only: - Cohort 1 only: Participants with Stage III (unresectable) or Stage IV (metastatic) melanoma that is considered nonamenable to curative treatments or procedures. - Cohort 2 only: Participants with histologically or cytologically confirmed recurrent/metastatic SCCHN that is PD-L1 positive (CPS = 1) which is not amenable to local therapy with curative intent. - Participants must have experienced disease progression after treatment with standard therapies, or are intolerant to or ineligible for standard treatment: 1. Part 1: All available standard therapies, including anti-PD-(L)1 and platinum-based therapy, if applicable, that are known to confer clinical benefit. Prior anti-PD-(L)1 therapy should not have been discontinued because of intolerance. 2. Part 2: Available standard therapies, including anti-PD-(L)1 and platinum-based therapy, if applicable, that are known to confer clinical benefit. Prior anti-PD-(L)1 therapy should not have been discontinued because of intolerance. Part 2 participants may have received up to 2 prior systemic therapies in the a advanced/metastatic setting. - ECOG performance status of 0 or 1 - Part 2 only: Measurable disease according to RECIST v1.1. - Part 2 only: Willingness to undergo a fresh tumor biopsy at screening (core or excisional). - Part 2 only: Willingness to undergo a fresh tumor biopsy at screening and on-treatment in selected participant. - Willingness to avoid pregnancy or fathering children Exclusion Criteria: - Prior treatment with any LAG-3- or MHC Class II-directed therapy for current malignancy, or any prior malignancy. - Treatment with anticancer therapies or participation in another interventional clinical study within 28 days before the first administration of study treatment (this includes curative radiation to the thorax or systemic anticancer therapies). - Not recovered to = Grade 1 or baseline from residual toxicities of prior therapy (with exceptions specified in the protocol). - Not recovered adequately from toxicities and/or complications from surgical intervention before starting study treatment. - Palliative radiation therapy administered within 1 week of first dose of study treatment or radiation therapy in the thoracic region that is > 30 Gy within 6 months of the first dose of study treatment. - Any known additional malignancy that is progressing or requires active treatment; history of other malignancy within 3 years of the first dose of study treatment (with exceptions specified in the protocol). - Evidence of interstitial lung disease or history of interstitial lung disease, or active, noninfectious pneumonitis. - Active autoimmune disease requiring systemic immunosuppression with corticosteroids (> 10 mg/day of prednisone or equivalent) or immunosuppressive drugs within 2 years before the first dose of study treatment. - Untreated brain or CNS metastases or brain or CNS metastases that have progressed (eg, evidence of new or enlarging brain metastasis or new neurological symptoms attributable to brain or CNS metastases). - Chronic treatment with systemic steroids (> 10 mg/day of prednisone or equivalent).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
INCA32459-101
solution for infusion

Locations

Country Name City State
Belgium Cliniques Universitaires Ucl Saint-Luc Bruxelles
Belgium Universitair Ziekenhuis Antwerpen (Uza) Edegem
Belgium Universitair Ziekenhuis Gent Gent
Belgium Universitair Ziekenhuis Brussel Jette
Belgium Chu Ucl Namur University Hospital Mont-Godinne Yvoir
Italy Centro Ricerche Cliniche Di Verona (Crc) Verona
Spain Hospital Quironsalud Barcelona Barcelona
Spain Ico Institut Catala D Oncologia L'hospitalet de Llobregat
Spain Centro Integral Oncologico Clara Campal Madrid
Spain Hospital Universitario 12 de Octubre Madrid
Spain Hospital Universitario Quironsalud Madrid Pozuelo de Alarcón
United States University of Texas Md Anderson Cancer Center Houston Texas
United States The Angeles Clinic and Research Institute Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
Incyte Corporation

Countries where clinical trial is conducted

United States,  Belgium,  Italy,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Part 1: Occurrence of Dose Limiting Toxicities (DLTs) Toxicities occurring during Part 1 will define tolerability. DLTs will be assessed for severity by the investigator using CTCAE v5.0 criteria. Up to approximately 12 months
Primary Number of Participants With Treatment Emergent Adverse Events (TEAEs) TEAE is any Adverse Event (AE) either reported for the first time or worsening of a pre-existing event after first dose of study drug. Up to approximately 12 months
Primary Number of Participants with Dose Interruptions due to TEAE Dose interruptions will occur according to protocol guidelines. Up to approximately 12 months
Primary Number of Participants discontinue study due to TEAE TEAE is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Up to approximately 12 months
Secondary Objective Response Rate (ORR) Defined as having Complete Response (CR) or Partial Response (PR), as determined by the investigator by radiographic disease assessment according to RECIST v1.1 or Lugano criteria (B-cell lymphomas only). Up to 12 months
Secondary Disease Control Response (DCR) Defined as having CR, PR, or Stable Disease (SD) as determined by the investigator by radiographic disease assessment according to RECIST v1.1. or Lugano criteria (B-cell lymphomas only). Up to 12 months
Secondary Duration of Response (DOR) Defined as the time from earliest date of disease response (Completed Response or Partial Response) until earliest date of disease progression as determined by the investigator by radiographic disease assessment according to RECIST v1.1 or Lugano criteria (B-cell lymphomas only) or death due to any cause if occurring sooner than progression. Up to 12 months
Secondary PK parameters: Cmax Defined as the maximum (peak) plasma drug concentration Up to 24 months
Secondary PK parameters: tmax Defined as the time to reach maximum (peak) plasma concentration following drug administration Up to 24 months
Secondary PK parameters: Cmin Defined as concentration at the end of the dosing interval Up to 24 months
Secondary PK Parameters: AUC Defined as the area under the plasma concentration-time curve Up to 24 months
Secondary PK Parameters: CL Defined as the apparent total body clearance of the drug from plasma Up to 24 months
Secondary PK Parameters: Vz Defined as apparent volume of distribution during terminal phase Up to 24 months
Secondary PK Parameters: t1/2 Defined as Elimination half-life (to be used in one-or noncompartmental model) Up to 24 months
Secondary Receptor Occupancy Defined as PD-1 receptor occupancy in peripheral blood samples. Up to 24 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Completed NCT00948961 - A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 Phase 1/Phase 2
Completed NCT03297424 - A Study of PLX2853 in Advanced Malignancies. Phase 1
Terminated NCT02265510 - An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies Phase 1/Phase 2
Completed NCT03907969 - A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers. Phase 1/Phase 2
Completed NCT03241173 - A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies Phase 1/Phase 2
Completed NCT02923349 - A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT04025957 - A Study of SHR-1501 in Patients With Advanced Tumors Phase 1
Recruiting NCT05048134 - A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies Phase 1
Completed NCT00651664 - A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies Phase 1
Not yet recruiting NCT06038058 - A Phase I Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies Phase 1
Completed NCT00611793 - PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies Phase 1
Recruiting NCT05891171 - Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers Phase 1
Not yet recruiting NCT05987605 - Clinical Study of 1A46 Drug Substance Phase 1
Terminated NCT02608268 - Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Phase 1/Phase 2
Terminated NCT03277352 - INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies Phase 1/Phase 2
Completed NCT04831996 - To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment. Phase 1
Recruiting NCT06468098 - A Study of IBI363 in Subjects With Advanced Malignancies Phase 1
Completed NCT02737501 - ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants Phase 3
Completed NCT03158272 - A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread Phase 1